Retour
Prix NervGen Pharma Corp. (NGENF)
Graphique du cours de l'action NGENF
NGENF Gagner
NervGen Pharma Corp.
$0
0%
$0
À la fermeture : Mar 23, 16:00:00 GMT-4
$0
0%
$0
Post-Marché: Mar 23, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
--
Prix d'ouverture
--
Plage de la journée
-
Plage de 52 semaines
-
Volume
--
Volume moyen
--
Rendement en dividend
--
BPA (TTM)
--
Capitalisation boursière
--
Qu’est-ce que NervGen Pharma Corp. ?
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.